|

Angio-immuno kinase inhibitor Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Sun Yat-sen University1

Indications

  • Limited-stage Small Cell Lung Cancer (LS-SCLC)1
  • Surufatinib1
  • Toripalimab1
  • Chemoradiotherapy1
  • Lung Cancer1

Other1 trial

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.